Literature DB >> 21664647

Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.

Alessandro Lugli1, Tatjana Vlajnic, Olivier Giger, Eva Karamitopoulou, Efstratios S Patsouris, George Peros, Luigi M Terracciano, Inti Zlobec.   

Abstract

In colorectal cancer, tumor budding at the invasive front (peritumoral budding) is an established prognostic parameter and decreased in mismatch repair-deficient tumors. In contrast, the clinical relevance of tumor budding within the tumor center (intratumoral budding) is not yet known. The aim of the study was to determine the correlation of intratumoral budding with peritumoral budding and mismatch repair status and the prognostic impact of intratumoral budding using 2 independent patient cohorts. Following pancytokeratin staining of whole-tissue sections and multiple-punch tissue microarrays, 2 independent cohorts (group 1: n = 289; group 2: n = 222) with known mismatch repair status were investigated for intratumoral budding and peritumoral budding. In group 1, intratumoral budding was strongly correlated to peritumoral budding (r = 0.64; P < .001) and less frequent in mismatch repair-deficient versus mismatch repair-proficient cases (P = .177). Sensitivity and specificity for lymph node positivity were 72.7% and 72.1%. In mismatch repair-proficient cancers, high-grade intratumoral budding was associated with right-sided location (P = .024), advanced T stage (P = .001) and N stage pN (P < .001), vascular invasion (P = .041), infiltrating tumor margin (P = .003), and shorter survival time (P = .014). In mismatch repair-deficient cancers, high intratumoral budding was linked to higher tumor grade (P = .004), vascular invasion (P = .009), infiltrating tumor margin (P = .005), and more unfavorable survival time (P = .09). These associations were confirmed in group 2. High-grade intratumoral budding was a poor prognostic factor in univariate (P < .001) and multivariable analyses (P = .019) adjusting for T stage, N stage distant metastasis, and adjuvant therapy. These preliminary results on 511 patients show that intratumoral budding is an independent prognostic factor, supporting the future investigation of intratumoral budding in larger series of both preoperative and postoperative rectal and colon cancer specimens.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664647     DOI: 10.1016/j.humpath.2011.02.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

1.  Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study.

Authors:  Lanqing Cao; Zhaoyong Wang; Liwei Duan; Lijuan Wei
Journal:  J Gastrointest Surg       Date:  2020-11-09       Impact factor: 3.452

2.  Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope?

Authors:  Fabio Grizzi; Giuseppe Celesti; Gianluca Basso; Luigi Laghi
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

Review 3.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

4.  Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study.

Authors:  Viktor H Koelzer; Inti Zlobec; Martin D Berger; Gieri Cathomas; Heather Dawson; Klaus Dirschmid; Marion Hädrich; Daniel Inderbitzin; Felix Offner; Giacomo Puppa; Walter Seelentag; Beat Schnüriger; Luigi Tornillo; Alessandro Lugli
Journal:  Virchows Arch       Date:  2015-02-21       Impact factor: 4.064

Review 5.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

6.  Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition.

Authors:  Raul S Gonzalez; Won Jae Huh; Justin M M Cates; Kay Washington; R Daniel Beauchamp; Robert J Coffey; Chanjuan Shi
Journal:  Histopathology       Date:  2016-10-28       Impact factor: 5.087

7.  Era of universal testing of microsatellite instability in colorectal cancer.

Authors:  Xuchen Zhang; Jia Li
Journal:  World J Gastrointest Oncol       Date:  2013-02-15

8.  A Comparison of Methods for Studying the Tumor Microenvironment's Spatial Heterogeneity in Digital Pathology Specimens.

Authors:  Ines Panicou Nearchou; Daniel Alexander Soutar; Hideki Ueno; David James Harrison; Ognjen Arandjelovic; Peter David Caie
Journal:  J Pathol Inform       Date:  2021-01-28

Review 9.  Tumour budding: a promising parameter in colorectal cancer.

Authors:  A Lugli; E Karamitopoulou; I Zlobec
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

10.  Role of intra- and peritumoral budding in the interdisciplinary management of rectal cancer patients.

Authors:  Inti Zlobec; Markus Borner; Alessandro Lugli; Daniel Inderbitzin
Journal:  Int J Surg Oncol       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.